Test Market/Actual Use Study Combination Proposed For Switch Candidates
This article was originally published in The Tan Sheet
Executive Summary
Consumer purchasing and use of potential Rx-to-OTC switch drugs may be most accurately predicted by a combination of actual use studies with a form of test marketing, according to Bristol-Myers Squibb Executive Medical Director Carola Friedman, MD
You may also be interested in...
Drug Manufacturer Interest In Rx-To-OTC Pipeline Growing – FDA’s Ganley
FDA is seeing increased activity from drug companies wanting to switch their prescription drug products over-the-counter, according to Center for Drug Evaluation & Research OTC Drug Products Division Director Charles Ganley, MD
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands